Defencath Solution
NDC Package 72990-103-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Defencath (taurolidine and heparin) solution is lIMITED POPULATION: DEFENCATH® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This formulation utilizes a solution delivery system. Marketed by Cormedix Inc., this product is identified by NDC 72990-103 and is authorized under FDA application NDA214520.

Identification & Billing

NDC Package Code
72990-103-10
Package Description
10 VIAL, SINGLE-DOSE in 1 CARTON / 3 mL in 1 VIAL, SINGLE-DOSE (72990-103-03)
Product Code
72990-103
11-Digit Billing Format
72990010310
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2670461 - heparin sodium, porcine 3,000 UNT / taurolidine 40.5 MG in 3 ML Injection
  • RxCUI: 2670461 - 3 ML heparin sodium, porcine 1000 UNT/ML / taurolidine 13.5 MG/ML Injection
  • RxCUI: 2670461 - heparin sodium, porcine 3,000 UNT / taurolidine 40.5 MG per 3 ML Injection
  • RxCUI: 2670468 - DEFENCATH 3000 UNT / 40.5 MG in 3 ML Injection
  • RxCUI: 2670468 - 3 ML heparin sodium, porcine 1000 UNT/ML / taurolidine 13.5 MG/ML Injection [Defencath]

Clinical Specifications

Proprietary Name
Defencath
Non-Proprietary Name
Taurolidine And Heparin
Substance Name
Heparin; Taurolidine
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Intraluminal - Administration within the lumen of a tube.
Active Ingredient(s)
Pharmacologic Class
Usage Information
LIMITED POPULATION: DEFENCATH® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients [see Clinical Studies (14)].Limitations of UseThe safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.

Regulatory & Marketing

Labeler Name
Cormedix Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA214520
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-09-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0911
Source: OPPS
Inst tauro 1.35mg/hep 100u
HCPCS Dosage taurolidine 1.35 mg and heparin sodium 100 units
Units / Pkg 300

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72990-103-10 identifies a specific commercial package of 10 vial, single-dose in 1 carton / 3 ml in 1 vial, single-dose (72990-103-03) of Defencath, a human prescription drug labeled by Cormedix Inc.. This solution is formulated for intraluminal use and contains heparin; taurolidine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cormedix Inc. on April 09, 2024. The current certification is valid through December 31, 2026.

How is this Cormedix Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72990010310. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72990-103-10
11-Digit CMS (5-4-2)
72990-0103-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.